We will relentlessly pursue treatments targeting SGK1 to enable people to live their absolute best lives.
Without Limits.
myQTwave is open for early beta enrollment for individuals with LQTS Types 2 and 3.
As we build toward broader participation, availability may be limited.
Learn more at www.myQTwave.com.
Our Focus:
Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1).
Breaking Barriers:
Isla Hutton
Long QT Type 3
We gain momentum everyday in our relentless pursuit of a treatment for Long QT Syndrome — In memory of Isla.
Together We Thryv
The enthusiasm of our investors is a reflection of breakthrough science, hard work and the dedication of our scientists, founders and collaborators.
Together we share a vision to transform the lives of people with life-threatening conditions.
Follow our journey
